The circadian clock, responsible for synchronizing physiological processes with the day-night cycle, has long been recognized for its influence on metabolism, cell cycle, and DNA repair. However, the precise mechanisms by which clock proteins affect cytoskeletal organization remained largely enigmatic. Now, the research team has provided compelling evidence that CLOCK and BMAL1, two core transcription factors integral to the molecular clock, directly stabilize and activate RHOA, a small GTPase essential for orchestrating F-actin filament formation, thereby affecting cancer cell dynamics and motility.

Through meticulous experimentation, the team demonstrated that CLOCK and BMAL1 interaction extends beyond their classical nuclear transcriptional roles into the realm of post-translational regulation. They stabilize RHOA protein levels within cancer cells, preventing its degradation while amplifying its activation state. This dual modulation ensures a robust and sustained assembly of filamentous actin (F-actin), a critical structural component that dictates cell shape, adhesion, and migration—a process that cancer cells exploit during metastasis.

Importantly, the study elucidates that the enhanced F-actin polymerization driven by CLOCK and BMAL1-facilitated RHOA activity leads to pronounced alterations in cellular architecture. Cancer cells display increased formation of stress fibers and focal adhesions, which collectively promote invasive phenotypes. By connecting chronobiology with cytoskeletal remodeling, this research highlights a previously unappreciated layer of complexity in how circadian machinery governs malignant cell behavior.

The implications of these findings resonate broadly across cancer biology and chronotherapy. They suggest that circadian regulators might serve as viable targets to impair the structural integrity that cancer cells depend on for dissemination. Moreover, therapeutic strategies that consider the timing of drug delivery relative to circadian oscillations could potentiate treatments aimed at RHOA signaling pathways, maximizing efficacy while minimizing adverse effects.

Analyzing the molecular interplay, researchers employed advanced live-cell imaging and biochemical assays to monitor RHOA activation states and F-actin dynamics. The precision of these techniques unveiled transient yet significant bursts of RHOA activity concomitant with CLOCK and BMAL1 expression cycles. This temporal coordination underscores the sophistication of circadian influences at the cytoskeletal interface, reflecting how intracellular timekeeping mechanisms fine-tune cellular behavior.

The study also maps out a potential signaling cascade, where CLOCK and BMAL1 may indirectly influence guanine nucleotide exchange factors (GEFs) or GTPase-activating proteins (GAPs) that regulate RHOA’s GTP-bound active state. By stabilizing RHOA, these clock proteins ensure a persistent pool of active GTPases, facilitating sustained actin filament nucleation and elongation. These mechanistic insights pave the way for future research to dissect the intermediary proteins and pathways involved.

Another fascinating aspect involves the post-translational modifications of RHOA influenced by CLOCK and BMAL1. The researchers identified alterations in ubiquitination patterns of RHOA dependent on circadian proteins, which affects its proteasomal degradation rates. This finding implicates the circadian clock not only in gene expression rhythms but in proteostasis critical for maintaining cytoskeletal regulators in cancer cells.

From a translational perspective, these results hint at novel biomarkers for cancer progression linked to circadian disruption. Aberrations in CLOCK and BMAL1 expression levels, or mutations altering their ability to stabilize RHOA, could serve as prognostic indicators of metastatic potential. Additionally, pharmacological modulation of these clock components may disrupt cancer cell invasiveness by destabilizing their cytoskeleton.

Critically, this research challenges the traditional compartmentalization of circadian clock functions, positioning these proteins as versatile regulators bridging gene expression, protein stability, and cell structure. This paradigm shift invites a reassessment of how circadian dysregulation contributes to oncogenesis and metastatic disease, reinforcing the need for integrated chronobiological approaches in cancer treatment.

Despite these advances, the study acknowledges limitations and calls for more in vivo validation of the CLOCK-BMAL1-RHOA axis in tumor models. Future investigations could explore temporal profiling of cytoskeletal proteins in patient-derived samples and the therapeutic impact of circadian modulators combined with cytoskeletal inhibitors.

In conclusion, the unveiling of CLOCK and BMAL1’s role in stabilizing and activating RHOA to promote F-actin formation not only enriches our molecular understanding of cancer cell biology but also underscores the intricate crosstalk between the circadian clock and cytoskeletal regulation. This research heralds new directions in cancer chronotherapy and highlights the potential to exploit temporal biological rhythms to disrupt malignancy at its structural core.

Subject of Research:
The molecular mechanisms by which circadian clock proteins CLOCK and BMAL1 regulate RHOA activity to facilitate F-actin cytoskeletal dynamics in cancer cells.

Article Title:
Author Correction: CLOCK and BMAL1 stabilize and activate RHOA to promote F-actin formation in cancer cells.

Article References:
Ma, Tj., Zhang, Zw., Lu, Yl. et al. Author Correction: CLOCK and BMAL1 stabilize and activate RHOA to promote F-actin formation in cancer cells. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01722-2

Image Credits: AI Generated

Phosphoinositides have long been appreciated for their roles at cellular membranes, notably the plasma membrane and various endomembrane compartments where they regulate cytoplasmic signaling cascades. However, this traditional view has been overturned by the discovery that PIPns also reside and function within the nucleus, creating elaborate signalosomes that integrate lipid signaling directly with nuclear events. These nuclear PIPns engage in more than just lipid metabolism; they participate actively in modulating chromatin remodeling, transcriptional control, and other nuclear processes essential for cancer progression.

At the heart of this nuclear signaling network lies the tumor suppressor p53, a protein renowned for its guardian role in maintaining genomic integrity. Intriguingly, both the wild-type and mutant forms of p53 have been demonstrated to serve as nuclear scaffolds that anchor PIPns, thereby facilitating the assembly of nuclear lipid-protein complexes. This anchoring capability enables p53 to orchestrate the formation of signalosomes that spatially and temporally regulate the nuclear lipid environment, directly influencing downstream targets that impact gene expression profiles, chromatin accessibility, and ultimately, cellular behavior related to motility and invasiveness.

One of the most striking revelations from this review is the demonstration of de novo AKT activation within the nucleus, a phenomenon distinct from the classical pathway of membrane-associated AKT activation. Nuclear AKT phosphorylation is triggered by PtdIns(3,4,5)P₃, synthesized within the nucleus by the PIPn-p53 complex, highlighting an autonomous nuclear signaling circuit. This nuclear AKT activation is pivotal for enhancing cancer cell survival and motility, especially in the context of cellular stress where traditional signaling routes might be compromised. It signifies an underappreciated axis by which tumor cells exploit nuclear lipid signaling to adapt and thrive.

The differential effects of wild-type versus mutant p53 in the context of nuclear PIPn signalosomes add further complexity. While wild-type p53 promotes tumor-suppressive functions and restrains cell migration, mutant p53 variants hijack the nuclear PIPn mechanism to foster oncogenic behaviors, substantially enhancing metastatic potential. This duality underscores how mutations in p53 reprogram nuclear lipid signaling pathways, transforming them from tumor inhibitors into facilitators of aggressive cancer phenotypes by modulating cytoskeletal rearrangements and transcriptional programs linked to invasion.

Beyond the fundamental biology, the elucidation of the nuclear PIPn-p53 signalosome opens promising therapeutic avenues. Targeting this nuclear lipid-protein assembly offers opportunities to disrupt maladaptive signaling that propels metastasis, particularly in cancers harboring mutant p53. Small molecules or biologics designed to interfere with nuclear-specific PIPn enzymes or to restore wild-type p53 function could synergistically enhance the efficacy of existing PI3K/AKT pathway inhibitors. This nuclear-centric approach to cancer therapy may represent a pivotal shift from membrane-bound signaling targets to those embedded within the nuclear microenvironment.

Furthermore, the spatial compartmentalization of lipid signaling within the nucleus challenges current paradigms of cellular signaling architecture. The presence of PIPns in chromatin-associated domains suggests a direct interface between lipid metabolism and epigenetic regulation, providing new perspectives on how nuclear lipids orchestrate gene regulatory networks. This crosstalk may have broader implications for understanding how cancer cells fine-tune transcriptional landscapes to adapt to environmental cues and therapeutic pressures.

Sophisticated imaging techniques and biochemical assays have been instrumental in uncovering the dynamics of the nuclear PIPn-p53 complex. Advanced microscopy coupled with lipid-binding probes has revealed the spatial distribution and assembly kinetics of signalosomes, while proteomic analyses have illuminated the multiplicity of protein interactors that modulate signalosome function. These methodologies underscore the intricate choreography of nuclear lipids and proteins in cancer, emphasizing the necessity of investigating nuclear lipid signaling in situ and at high resolution.

The intersection between lipid signaling and cytoskeletal dynamics represents another frontier elucidated by this review. By integrating nuclear lipid cues with the regulation of actin and other cytoskeletal components, the PIPn-p53 signalosome acts as a critical conduit translating nuclear events into morphological and mechanical changes that facilitate cell motility. This integration is especially relevant for metastatic dissemination, wherein cancer cells must traverse complex extracellular matrices and evade immune surveillance.

Moreover, the nuclear PIPn-p53 signalosome exemplifies how oncoproteins and tumor suppressors can repurpose canonical signaling modules within distinct cellular compartments to achieve context-dependent outcomes. The nuclear residency of these complexes challenges the long-held notion that lipid signaling is predominantly cytoplasmic and urges a reevaluation of nuclear lipidomes as not only structural entities but as active signaling platforms intimately tied to oncogenic reprogramming.

As we look toward future research, dissecting the regulatory mechanisms governing the assembly, disassembly, and post-translational modifications of the nuclear PIPn-p53 signalosome remains a high priority. Understanding how extracellular signals impinge on this nuclear hub and how it integrates with genome stability pathways could uncover novel vulnerabilities in aggressive cancers. Additionally, the development of selective nuclear PIPn enzyme inhibitors with favorable pharmacodynamics and minimal off-target effects represents a formidable but promising challenge.

In summary, the unveiling of the nuclear phosphoinositide-p53 signalosome represents a conceptual leap in cancer cell biology, highlighting how lipid signaling transcends traditional boundaries to influence nuclear function and cancer metastasis. It integrates two major oncogenic pathways — p53 dysfunction and PI3K-AKT signaling amplification — into a unified nuclear mechanism that controls cancer cell motility. This discovery not only enriches our understanding of tumor biology but also charts new directions for therapeutic intervention aimed at curtailing cancer spread by targeting nuclear lipid signaling nodes.

Subject of Research: Not applicable
Article Title: The nuclear phosphoinositide-p53 signalosome in the regulation of cell motility
News Publication Date: 26-May-2025
Web References: 10.1093/procel/pwaf043
Image Credits: Xiaoting Hou, Yu Chen, Bo Zhou, Fengting Liu, Lingyun Dai, Chunbo Chen, Noah D. Carrillo, Vincent L. Cryns, Richard A. Anderson, Jichao Sun, Mo Chen
Keywords: Cells, Phosphoinositides, p53, AKT activation, Nuclear signaling, Cancer cell motility, Metastasis, Signalosome, Lipid signaling, PI3K-AKT pathway, Nuclear lipid metabolism, Cytoskeletal dynamics

The actin cytoskeleton is a fundamental cellular scaffold responsible for maintaining cell shape, enabling motility, and facilitating intracellular transport. Its dynamic remodeling is especially crucial in pathological contexts, such as cancer progression and metastasis, where enhanced cell migration allows malignant cells to invade surrounding tissues and establish secondary tumors. It is well-known that ROS, a group of highly reactive molecules derived from oxygen metabolism, act as intracellular signaling mediators influencing various cellular processes, including cytoskeletal rearrangements.

Previous studies have demonstrated that Transient Receptor Potential Melastatin 2 (TRPM2) channels, a type of calcium-permeable ion channel, can be activated by oxidative stress stimuli like hydrogen peroxide (H₂O₂), leading to altered intracellular ion dynamics. However, prior to this current investigation, the exact mechanisms by which TRPM2 channels influence actin remodeling in the context of pathophysiologically relevant ROS generation remained largely unexplored, particularly in prostate cancer cells.

The research team focused on two widely used prostate cancer cell lines, PC-3 and DU145, to emulate the tumor environment and investigate how endogenously produced ROS affect actin filament organization and cell migration. Through a combination of molecular probes and advanced imaging techniques, they intricately mapped the cellular responses to ROS and dissected the role of TRPM2 channels in this process.

Specifically, the study employed phalloidin staining and expression of pActin-tdTomato constructs to visualize actin structures at high resolution with confocal microscopy. This approach allowed for precise delineation of cytoskeletal changes triggered by ROS in live cells. To monitor intracellular metal ion dynamics, the team used Fluozin3-AM and Fluo4-AM probes to detect fluctuations in zinc (Zn²⁺) and calcium (Ca²⁺) concentrations, respectively—both ions playing critical regulatory roles in cytoskeletal modulation.

The results revealed a striking phenomenon: exposure to H₂O₂ and saturated fatty acid palmitate elicited significant TRPM2-dependent increases in cytosolic Ca²⁺ and Zn²⁺. These ion surges were directly implicated in promoting extensive actin remodeling, characterized by reorganization of actin filaments, which in turn facilitated enhanced migratory behavior in both PC-3 and DU145 cells.

Further validation came from experiments involving pharmacological inhibitors of TRPM2 channels and genetic knockdown techniques. When TRPM2 function was abrogated, the ROS-induced elevations in intracellular Ca²⁺ and Zn²⁺ were markedly suppressed. Consequently, actin remodeling responses and cell migration capabilities were significantly diminished, affirming the essential role of TRPM2 in translating ROS signals into cytoskeletal dynamics.

Moreover, the study highlighted the importance of Zn²⁺ homeostasis in this signaling axis. Chelation of Zn²⁺ ions via selective binding agents impaired the actin remodeling process, underscoring zinc as a critical secondary messenger downstream of TRPM2 activation. This novel insight challenges the traditionally calcium-centric view of ion-mediated cytoskeletal regulation, opening new avenues for understanding zinc’s contribution to cancer cell motility.

From a mechanistic perspective, the dual regulation of Ca²⁺ and Zn²⁺ by TRPM2 channels appears to orchestrate a finely tuned signaling cascade that ultimately remodels the actin network. This remodeling is essential for the cellular morphological changes and protrusive activities required for directed migration—key processes in metastatic dissemination of cancer cells.

The clinical implications of this discovery are profound. Targeting TRPM2 channels or modulating intracellular Zn²⁺ levels might serve as innovative therapeutic approaches to hinder cancer cell migration and metastasis. Given the aggressive nature of prostate cancer and its capacity for widespread dissemination, interventions that disrupt this newly uncovered signaling pathway could significantly impact patient outcomes and survival rates.

Future research stemming from this work will likely focus on delineating the precise molecular targets of Zn²⁺ within the cytoskeletal framework and identifying signaling intermediates modulated by TRPM2 activation. Understanding these downstream effectors will enhance our capacity to design specific drugs capable of blocking metastatic progression without compromising normal cellular functions.

Additionally, the potential cross-talk between TRPM2-mediated ion fluxes and other cellular signaling networks remains an exciting field for exploration. ROS-dependent pathways intersect multiple metabolic and transcriptional cascades, and unraveling these interactions could reveal broader systemic effects of TRPM2 regulation in cancer biology.

This study also raises interesting questions regarding the role of lipid-derived ROS, such as palmitate-induced oxidative stress, in cancer cell behavior. The apparent ability of fatty acids to activate TRPM2 channels and orchestrate cytoskeletal plasticity highlights the intricate relationship between metabolic alterations and cancer progression.

In summary, the elucidation of TRPM2 channels as crucial mediators linking oxidative stress to actin cytoskeleton remodeling and enhanced cell migration paints a comprehensive picture of a complex signaling axis operative in prostate cancer cells. The discovery accentuates the multifaceted role of ion channels in cancer biology and underscores the therapeutic promise of targeting these pathways.

As researchers continue to dissect the nuances of ROS signaling and TRPM2 function, the field moves closer to translating these fundamental insights into tangible clinical interventions. This paradigm shift towards ion channel-targeted therapies could redefine strategies aimed at combating metastatic prostate cancer and improve prognosis for countless patients.

The findings in this study represent a monumental step forward in our understanding of the interplay between oxidative stress, ion channel regulation, and cytoskeletal dynamics in cancer metastasis. They offer a compelling rationale for integrating molecular ion channel modulators into the armamentarium of cancer therapeutics, heralding a new era of precision medicine tailored to disrupt the metastatic cascade at its core.

Subject of Research: TRPM2 channel-mediated reactive oxygen species (ROS)-induced actin remodeling and cell migration mechanisms in prostate cancer cells

Article Title: TRPM2 channels mediate ROS-induced actin remodeling and cell migration of prostate cancer cells

Article References:
Qi, P., Zhao, J., Zhang, H. et al. TRPM2 channels mediate ROS-induced actin remodeling and cell migration of prostate cancer cells. BMC Cancer 25, 956 (2025). https://doi.org/10.1186/s12885-025-14333-3

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14333-3